Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients.
The company offers its products directly to customers, as well as through third-party distributors and sub-distributors.
It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss.
The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014.
The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 24 | 0.25 Increased by +238.89% | -0.14 Increased by +278.57% |
| May 9, 24 | -0.03 Increased by +72.73% | -0.21 Increased by +85.71% |
| Feb 28, 24 | -0.17 Decreased by -142.86% | -0.27 Increased by +37.04% |
| Nov 8, 23 | -0.18 Decreased by -200.00% | -0.40 Increased by +55.00% |
| Aug 8, 23 | -0.18 Decreased by -38.46% | -0.31 Increased by +41.94% |
| May 10, 23 | -0.11 Increased by +15.38% | -0.11 |
| Feb 27, 23 | -0.07 Decreased by -133.33% | -0.09 Increased by +22.22% |
| Nov 3, 22 | -0.06 Decreased by -185.71% | -0.14 Increased by +57.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 82.88 M Increased by +23.35% | -7.41 M Increased by +68.46% | Decreased by -8.94% Increased by +74.43% |
| Jun 30, 24 | 92.27 M Increased by +31.26% | -1.39 M Increased by +94.41% | Decreased by -1.51% Increased by +95.74% |
| Mar 31, 24 | 72.05 M Decreased by -6.75% | -16.66 M Increased by +29.85% | Decreased by -23.12% Increased by +24.78% |
| Dec 31, 23 | 65.57 M Decreased by -20.41% | -118.10 M Decreased by -544.32% | Decreased by -180.11% Decreased by -709.55% |
| Sep 30, 23 | 67.19 M Decreased by -15.33% | -23.48 M Decreased by -38.64% | Decreased by -34.95% Decreased by -63.75% |
| Jun 30, 23 | 70.30 M Decreased by -12.81% | -24.95 M Decreased by -15.01% | Decreased by -35.49% Decreased by -31.91% |
| Mar 31, 23 | 77.26 M Decreased by -2.71% | -23.75 M Decreased by -20.87% | Decreased by -30.74% Decreased by -24.24% |
| Dec 31, 22 | 82.38 M Increased by +3.99% | -18.33 M Decreased by -13.49% | Decreased by -22.25% Decreased by -9.13% |